Exosomes as divine messengers: Are they the Hermes of modern molecular oncology?

Cell Death and Differentiation

Volumn 22, Issue 1, 2015, Pages 34-45

  Braicu, C ^a   Tomuleasa, C ^a,b   Monroig, P ^c,d   Cucuianu, A ^a,b   Berindan Neagoe, I ^a   Calin, G A ^c  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; RNA;

ANIMAL; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; EXOSOME; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METASTASIS; NEOPLASM; PATHOLOGY; PROTEIN SYNTHESIS; TUMOR INVASION;

ANIMALS; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; EXOSOMES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN BIOSYNTHESIS; RNA, NEOPLASM;

EID: 84928032376     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.130     Document Type: Review

References (114)

1. Brown NO. Hermes the Thief; the Evolution of a Myth. University of Wisconsin Press: Madison, 1947; vi, pp 164.
2. Soekmadji C, Russell PJ, Nelson CC. Exosomes in prostate cancer: Putting together the pieces of a puzzle. Cancers (Basel) 2013; 5: 1522-1544.
3. Oskarsson T, Batlle E, Massague J. Metastatic stem cells: Sources, niches, and vital pathways. Cell Stem Cell 2014; 14: 306-321.
4. Gyorgy B, Szabo TG, Pasztoi M, Pal Z, Misjak P, Aradi B et al. Membrane vesicles, current state-of-the-art: Emerging role of extracellular vesicles. Cell Mol Life Sci 2011; 68: 2667-2688.
5. Zhang HG, Zhuang X, Sun D, Liu Y, Xiang X, Grizzle WE. Exosomes and immune surveillance of neoplastic lesions: A review. Biotech Histochem 2012; 87: 161-168.
6. Fabian MR, Sonenberg N, Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 2010; 79: 351-379.
7. Ambros V. MicroRNA pathways in flies and worms: Growth, death, fat, stress, and timing. Cell 2003; 113: 673-676.
8. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell 2005; 122: 6-7.
9. Spizzo R, Almeida MI, Colombatti A, Calin GA. Long non-coding RNAs and cancer: A new frontier of translational research? Oncogene 2012; 31: 4577-4587.
10. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008; 105: 5166-5171.
11. Calin GA, Croce CM. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 2006; 25: 6202-6210.
12. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-866.
13. Rak J, Guha A. Extracellular vesicles-vehicles that spread cancer genes. Bioessays 2012; 34: 489-497.
14. Alderton GK. Metastasis. Exosomes drive premetastatic niche formation. Nat Rev Cancer 2012; 12: 447.
15. Thery C, Zitvogel L, Amigorena S. Exosomes: Composition, biogenesis and function. Nat Rev Immunol 2002; 2: 569-579.
16. Simons M, Raposo G. Exosomes-vesicular carriers for intercellular communication. Curr Opin Cell Biol 2009; 21: 575-581.
17. Simpson RJ, Lim JW, Moritz RL, Mathivanan S. Exosomes: Proteomic insights and diagnostic potential. Expert Rev Proteomics 2009; 6: 267-283.
18. Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA et al. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods 2001; 247(1-2): 163-174.
19. Rana S, Malinowska K, Zoller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 2013; 15: 281-295.
20. Lotvall J, Valadi H. Cell to cell signalling via exosomes through esRNA. Cell Adh Migr 2007; 1: 156-158.
21. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. Traffic 2002; 3: 321-330.
22. Thery C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 2009; 9: 581-593.
23. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: Extracellular vesicles for genetic information transfer and gene therapy. Hum Mol Genet 2012; 21(R1): R125-R134.
24. Mathivanan S, Simpson RJ. ExoCarta: A compendium of exosomal proteins and RNA. Proteomics 2009; 9: 4997-5000.
25. Huang X, Yuan T, Tschannen M, Sun Z, Jacob H, Du M et al. Characterization of human plasma-derived exosomal RNAs by deep sequencing. BMC Genomics 2013; 14: 319.
26. Pfeffer SR. Two Rabs for exosome release. Nat Cell Biol 2010; 12: 3-4.
27. Ostrowski M, Carmo NB, Krumeich S, Fanget I, Raposo G, Savina A et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol 2010; 12: 19-30; sup pp 1-13.
28. Thery C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999; 147: 599-610.
29. Buschow SI, Nolte-'t Hoen EN, Van Niel G, Pols MS, ten Broeke T, Lauwen M et al. MHC II in dendritic cells is targeted to lysosomes or T cell-induced exosomes via distinct multivesicular body pathways. Traffic 2009; 10: 1528-1542.
30. Denzer K, Van Eijk M, Kleijmeer MJ, Jakobson E, De Groot C, Geuze HJ. Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol 2000; 165: 1259-1265.
31. Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: Mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol 2011; 33: 441-454.
32. Black PH. Shedding from normal and cancer-cell surfaces. N Engl J Med 1980; 303: 1415-1416.
33. Pap E, Pallinger E, Pasztoi M, Falus A. Highlights of a new type of intercellular communication: Microvesicle-based information transfer. Inflamm Res 2009; 58: 1-8.
34. Gu J, Qian H, Shen L, Zhang X, Zhu W, Huang L et al. Gastric cancer exosomes trigger differentiation of umbilical cord derived mesenchymal stem cells to carcinoma-associated fibroblasts through TGF-beta/Smad pathway. PLoS One 2012; 7: E52465.
35. Kahlert C, Kalluri R. Exosomes in tumor microenvironment influence cancer progression and metastasis. J Mol Med (Berl) 2013; 91: 431-437.
36. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144: 646-674.
37. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S et al. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008; 15: 80-88.
38. Whiteside TL. Tumour-derived exosomes or microvesicles: Another mechanism of tumour escape from the host immune system? Br J Cancer 2005; 92: 209-211.
39. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001; 7: 297-303.
40. Yang L, Wu XH, Wang D, Luo CL, Chen LX. Bladder cancer cell-derived exosomes inhibit tumor cell apoptosis and induce cell proliferation in vitro. Mol Med Rep 2013; 8: 1272-1278.
41. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, Blagosklonny MV et al. Molecular definitions of cell death subroutines: Recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ 2012; 19: 107-120.
42. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res 2011; 39: 7223-7233.
43. Zomer A, Vendrig T, Hopmans ES, Van Eijndhoven M, Middeldorp JM, Pegtel DM. Exosomes: Fit to deliver small RNA. Commun Integr Biol 2010; 3: 447-450.
44. Turchinovich A, Weiz L, Burwinkel B. Extracellular miRNAs: The mystery of their origin and function. Trends Biochem Sci 2012; 37: 460-465.
45. Clayton A, Mason MD. Exosomes in tumour immunity. Curr Oncol 2009; 16: 46-49.
46. Liu C, Yu S, Zinn K, Wang J, Zhang L, Jia Y et al. Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J Immunol 2006; 176: 1375-1385.
47. Okoye IS, Coomes SM, Pelly VS, Czieso S, Papayannopoulos V, Tolmachova T et al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. Immunity 2014; 41: 89-103.
48. Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med 2012; 10: 134.
49. Vigorito E, Kohlhaas S, Lu D, Leyland R. miR-155: An ancient regulator of the immune system. Immunol Rev 2013; 253: 146-157.
50. Stahl HF, Fauti T, Ullrich N, Bopp T, Kubach J, Rust W et al. miR-155 inhibition sensitizes CD4 Th cells for TREG mediated suppression. PLoS One 2009; 4: E7158.
51. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-659.
52. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518.
53. Skog J, Wurdinger T, Van Rijn S, Meijer DH, Gainche L, Sena-Esteves M et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470-1476.
54. Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, Watanabe Y et al. Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One 2010; 5: E13247.
55. Khan S, Jutzy JM, Aspe JR, McGregor DW, Neidigh JW, Wall NR. Survivin is released from cancer cells via exosomes. Apoptosis 2011; 16: 1-12.
56. Peinado H, Lavotshkin S, Lyden D. The secreted factors responsible for pre-metastatic niche formation: Old sayings and new thoughts. Semin Cancer Biol 2011; 21: 139-146.
57. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18: 883-891.
58. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR et al. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell 2014; 25: 501-515.
59. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 2012; 227: 658-667.
60. Abdel-Razeq H, Marei L. Current neoadjuvant treatment options for HER2-positive breast cancer. Biologics 2011; 5: 87-94.
61. Nahta R, Esteva FJ. HER2 therapy: Molecular mechanisms of trastuzumab resistance. Breast Cancer Res 2006; 8: 215.
62. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: Understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006; 3: 269-280.
63. Xiao D, Ohlendorf J, Chen Y, Taylor DD, Rai SN, Waigel S et al. Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One 2012; 7: E46874.
64. Lehmann SM, Kruger C, Park B, Derkow K, Rosenberger K, Baumgart J et al. An unconventional role for miRNA: Let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat Neurosci 2012; 15: 827-835.
65. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R et al. MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA 2012; 109: E2110-E2116.
66. Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood 2013; 122: 1891-1899.
67. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer 2012; 106: 768-774.
68. Yang M, Chen J, Su F, Yu B, Su F, Lin L et al. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Mol Cancer 2011; 10: 117.
69. O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM et al. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer 2013; 49: 1845-1859.
70. Paidpally V, Chirindel A, Lam S, Agrawal N, Quon H, Subramaniam RM. FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma. Imaging Med 2012; 4: 633-647.
71. Wu C, Li F, Niu G, Chen X. PET imaging of inflammation biomarkers. Theranostics 2013; 3: 448-466.
72. Anderson NG, Butler AP. Clinical applications of spectral molecular imaging: Potential and challenges. Contrast Media Mol Imaging 2014; 9: 3-12.
73. Felgueiras J, Silva JV, Fardilha M. Prostate cancer: The need for biomarkers and new therapeutic targets. J Zhejiang Univ Sci B 2014; 15: 16-42.
74. Yang H, Zhu L, Wang S, Lang J, Xu T. Noninvasive diagnosis of moderate to severe endometriosis: The platelet-lymphocyte ratio cannot be a neoadjuvant biomarker for serum cancer antigen 125. J Minim Invasive Gynecol 2013; e-pub ahead of print 10 July 2013; doi:10.1016/j.jmig.2013.06.003.
75. Cho JA, Park H, Lim EH, Lee KW. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int J Oncol 2012; 40: 130-138.
76. Sharma P, Sahni NS, Tibshirani R, Skaane P, Urdal P, Berghagen H et al. Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res 2005; 7: R634-R644.
77. Aaroe J, Lindahl T, Dumeaux V, Saebo S, Tobin D, Hagen N et al. Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res 2010; 12: R7.
78. Showe MK, Vachani A, Kossenkov AV, Yousef M, Nichols C, Nikonova EV et al. Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res. 2009; 69: 9202-9210.
79. Chaput N, Taieb J, Schartz NE, Andre F, Angevin E, Zitvogel L. Exosome-based immunotherapy. Cancer Immunol Immunother 2004; 53: 234-239.
80. Hao S, Bai O, Yuan J, Qureshi M, Xiang J. Dendritic cell-derived exosomes stimulate stronger CD8 CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol 2006; 3: 205-211.
81. Viaud S, Terme M, Flament C, Taieb J, Andre F, Novault S et al. Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: A role for NKG2D ligands and IL-15Ralpha. PLoS One 2009; 4: E4942.
82. Chaput N, Schartz NE, Andre F, Taieb J, Novault S, Bonnaventure P et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 2004; 172: 2137-2146.
83. Chen W, Wang J, Shao C, Liu S, Yu Y, Wang Q et al. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells. Eur J Immunol 2006; 36: 1598-1607.
84. Nilsson J, Skog J, Nordstrand A, Baranov V, Mincheva-Nilsson L, Breakefield XO et al. Prostate cancer-derived urine exosomes: A novel approach to biomarkers for prostate cancer. Br J Cancer 2009; 100: 1603-1607.
85. Pant S, Hilton H, Burczynski ME. The multifaceted exosome: Biogenesis, role in normal and aberrant cellular function, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol 2012; 83: 1484-1494.
86. Bu N, Li QL, Feng Q, Sun BZ. Immune protection effect of exosomes against attack of L1210 tumor cells. Leuk Lymphoma 2006; 47: 913-918.
87. Guo F, Chang CK, Fan HH, Nie XX, Ren YN, Liu YY et al. Anti-tumour effects of exosomes in combination with cyclophosphamide and polyinosinic-polycytidylic acid. J Int Med Res 2008; 36: 1342-1353.
88. Xiu F, Cai Z, Yang Y, Wang X, Wang J, Cao X. Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes. J Mol Med (Berl) 2007; 85: 511-521.
89. Marimpietri D, Petretto A, Raffaghello L, Pezzolo A, Gagliani C, Tacchetti C et al. Proteome profiling of neuroblastoma-derived exosomes reveal the expression of proteins potentially involved in tumor progression. PLoS One 2013; 8: E75054.
90. Mineo M, Garfield SH, Taverna S, Flugy A, De Leo G, Alessandro R et al. Exosomes released by K562 chronic myeloid leukemia cells promote angiogenesis in a Src-dependent fashion. Angiogenesis 2012; 15: 33-45.
91. Tiryakioglu D, Bilgin E, Holdenrieder S, Dalay N, Gezer U. miR-141 and miR-375 induction and release are different from PSA mRNA and PCA3 upon androgen stimulation of LNCaP cells. Biomed Rep 2013; 1: 802-806.
92. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110: 13-21.
93. Rosell R, Wei J, Taron M. Circulating microRNA signatures of tumor-derived exosomes for early diagnosis of non-small-cell lung cancer. Clin Lung Cancer 2009; 10: 8-9.
94. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: A diagnostic marker for lung cancer. Clin Lung Cancer 2009; 10: 42-46.
95. Takeshita N, Hoshino I, Mori M, Akutsu Y, Hanari N, Yoneyama Y et al. Serum microRNA expression profile: MiR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer 2013; 108: 644-652.
96. Ohno S, Takanashi M, Sudo K, Ueda S, Ishikawa A, Matsuyama N et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther 2013; 21: 185-191.
97. EL Andaloussi S, Mager I, Breakefield XO, Wood MJ. Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat Rev Drug Discov 2013; 12: 347-357.
98. Amigorena S. Anti-tumour immunotherapy using dendritic-cell-derived exosomes. Res Immunol 1998; 149(7-8): 661-662.
99. Hu G, Yao H, Chaudhuri AD, Duan M, Yelamanchili SV, Wen H et al. Exosome-mediated shuttling of microRNA-29 regulates HIV Tat and morphine-mediated neuronal dysfunction. Cell Death Dis 2012; 3: E381.
100. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011; 29: 341-345.
101. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D et al. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med 1998; 4: 594-600.
102. Andre F, Schartz NE, Movassagh M, Flament C, Pautier P, Morice P et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002; 360: 295-305.
103. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013; 12: 847-865.
104. Martinez MC, Andriantsitohaina R. Microparticles in angiogenesis: Therapeutic potential. Circ Res 2011; 109: 110-119.
105. Patel S, Mehta-Damani A, Shu H, Le Pecq JB. An analysis of variability in the manufacturing of dexosomes: Implications for development of an autologous therapy. Biotechnol Bioeng 2005; 92: 238-249.
106. Le Pecq JB. Dexosomes as a therapeutic cancer vaccine: From bench to bedside. Blood Cells Mol Dis 2005; 35: 129-135.
107. Bachmann MF, Jennings GT. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010; 10: 787-796.
108. Lee EY, Park KS, Yoon YJ, Lee J, Moon HG, Jang SC et al. Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis. PLoS One 2012; 7: E33330.
109. Wahlgren J, De LKT, Brisslert M, Vaziri Sani F, Telemo E, Sunnerhagen P et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res 2012; 40: E130.
110. El-Andaloussi S, Lee Y, Lakhal-Littleton S, Li J, Seow Y, Gardiner C et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc 2012; 7: 2112-2126.
111. Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal 2013; 11: 88.
112. Ristorcelli E, Beraud E, Mathieu S, Lombardo D, Verine A. Essential role of Notch signaling in apoptosis of human pancreatic tumoral cells mediated by exosomal nanoparticles. Int J Cancer 2009; 125: 1016-1026.
113. Ristorcelli E, Beraud E, Verrando P, Villard C, Lafitte D, Sbarra V et al. Human tumor nanoparticles induce apoptosis of pancreatic cancer cells. FASEB J 2008; 22: 3358-3369.
114. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ. Delivery of siRNA the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 2011; 29: 341-345.